{"id":"g-chop","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":null,"effect":"Peripheral neuropathy (vincristine-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"G-CHOP is a polychemotherapy combination where gemcitabine acts as an antimetabolite, cyclophosphamide and doxorubicin are alkylating agents and topoisomerase II inhibitors respectively, and vincristine is a microtubule inhibitor. Together, these agents target different phases of the cell cycle and DNA synthesis to induce apoptosis in malignant cells, commonly used in lymphoma treatment.","oneSentence":"G-CHOP is a chemotherapy regimen combining gemcitabine, cyclophosphamide, doxorubicin, and vincristine (Oncovin) to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:39.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphoma (likely non-Hodgkin lymphoma or Hodgkin lymphoma)"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":"Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type","enrollment":20},{"nctId":"NCT06186648","phase":"PHASE2","title":"Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome","status":"RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2024-03-21","conditions":"Richter Syndrome","enrollment":40},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT00278408","phase":"PHASE3","title":"Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2006-01-02","conditions":"Lymphoma","enrollment":700},{"nctId":"NCT00945724","phase":"PHASE2","title":"Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-09-27","conditions":"Large B-cell Diffuse Lymphoma of Testis","enrollment":54},{"nctId":"NCT06901999","phase":"PHASE2","title":"Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04","conditions":"CNS Lymphoma","enrollment":23},{"nctId":"NCT05350930","phase":"","title":"Multidisciplinary Care Program to Secure MEdication Therapy for HematoLOgy Patients Receiving Injectable Anticancer Drugs","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2022-06-09","conditions":"Chemotherapy Effect, G-CHOP Chemotherapy, R-CHOP Chemotherapy","enrollment":38},{"nctId":"NCT06151080","phase":"PHASE2","title":"Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-11-22","conditions":"DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma","enrollment":38},{"nctId":"NCT03467373","phase":"PHASE1","title":"A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-03-13","conditions":"B-Cell Lymphoma, Non-Hodgkin Lymphoma","enrollment":111},{"nctId":"NCT06739265","phase":"PHASE1, PHASE2","title":"Golidocitinib Plus CHOP in Newly Diagnosed PTCL","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-09-01","conditions":"Peripheral T-cell Lymphoma","enrollment":68},{"nctId":"NCT06284122","phase":"PHASE3","title":"Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2024-06-07","conditions":"Follicular Lymphoma","enrollment":790},{"nctId":"NCT06474481","phase":"PHASE2","title":"Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07","conditions":"FL","enrollment":30},{"nctId":"NCT02073097","phase":"PHASE1, PHASE2","title":"Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-01-28","conditions":"Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma","enrollment":48},{"nctId":"NCT03650933","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients","status":"UNKNOWN","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2018-12-28","conditions":"Diffuse Large B-Cell Lymphoma, Unspecified Site","enrollment":360},{"nctId":"NCT05968001","phase":"","title":"Obinutuzumab in Chinese Real-world Patients With iNHL","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2023-07-20","conditions":"Lymphomas Non-Hodgkin's B-Cell","enrollment":400},{"nctId":"NCT01746173","phase":"PHASE2","title":"CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-07","conditions":"T-cell Non-Hodgkin Lymphoma","enrollment":5},{"nctId":"NCT00324467","phase":"PHASE2","title":"Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma","enrollment":150},{"nctId":"NCT02596971","phase":"PHASE1, PHASE2","title":"A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-22","conditions":"Diffuse Large B-Cell Lymphoma, Lymphoma Follicular","enrollment":91},{"nctId":"NCT00058422","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-02-10","conditions":"Lymphoma","enrollment":65},{"nctId":"NCT02445404","phase":"PHASE2","title":"Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2015-09-23","conditions":"Peripheral T-cell Lymphoma","enrollment":134},{"nctId":"NCT00101010","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09","conditions":"Lymphoma","enrollment":80},{"nctId":"NCT02055820","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-17","conditions":"Lymphoma, Non-Hodgkin","enrollment":267},{"nctId":"NCT00290498","phase":"PHASE2","title":"Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-08-01","conditions":"Lymphoma","enrollment":67},{"nctId":"NCT00211185","phase":"PHASE2","title":"A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2004-03-14","conditions":"Lymphoma, T-Cell, Peripheral","enrollment":49},{"nctId":"NCT02890602","phase":"PHASE2","title":"Erythropoietin for Management of Anemia Caused by Chemotherapy","status":"COMPLETED","sponsor":"Kosin University Gospel Hospital","startDate":"2012-09-01","conditions":"Diffuse Large B-cell Lymphoma","enrollment":53},{"nctId":"NCT03619993","phase":"NA","title":"Patient Preference for Pegfilgrastim (Neulasta®) Application Forms","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2018-06-25","conditions":"Non Hodgkin Lymphoma, Breast Cancer","enrollment":404},{"nctId":"NCT01287741","phase":"PHASE3","title":"A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-26","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1418},{"nctId":"NCT00646854","phase":"PHASE3","title":"Alemtuzumab and CHOP in T-cell Lymphoma","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2008-06","conditions":"Lymphoma, T-Cell, Peripheral","enrollment":136},{"nctId":"NCT00530179","phase":"NA","title":"FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"AHS Cancer Control Alberta","startDate":"2007-07","conditions":"Diffuse Large B Cell Lymphoma","enrollment":69},{"nctId":"NCT02858258","phase":"PHASE3","title":"ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Prof. Dr. M. Dreyling (co-chairman)","startDate":"2016-07","conditions":"Mantle Cell Lymphoma","enrollment":870},{"nctId":"NCT02871869","phase":"PHASE2, PHASE3","title":"Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Xinjiang Medical University","startDate":"2016-09","conditions":"Diffuse, Large B-Cell, Lymphoma","enrollment":316},{"nctId":"NCT02670317","phase":"PHASE2","title":"Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.","status":"TERMINATED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2016-09","conditions":"Lymphoma, B-Cell","enrollment":1},{"nctId":"NCT01763398","phase":"","title":"Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-09","conditions":"Non-Hodgkin's Lymphoma","enrollment":500},{"nctId":"NCT00145002","phase":"PHASE3","title":"A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)","status":"COMPLETED","sponsor":"Japan Clinical Oncology Group","startDate":"1998-08","conditions":"Adult T-cell Leukemia, Lymphoma","enrollment":130},{"nctId":"NCT00147121","phase":"PHASE2, PHASE3","title":"Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)","status":"COMPLETED","sponsor":"Haruhiko Fukuda","startDate":"2002-09","conditions":"Lymphoma, B-Cell","enrollment":300},{"nctId":"NCT01793844","phase":"","title":"A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2008-01","conditions":"Diffuse Large B-cell Lymphoma","enrollment":732},{"nctId":"NCT00337987","phase":"PHASE2","title":"A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-11","conditions":"Peripheral T-Cell Lymphoma","enrollment":49},{"nctId":"NCT00379574","phase":"PHASE1, PHASE2","title":"Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2006-09","conditions":"Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell","enrollment":49},{"nctId":"NCT00209222","phase":"PHASE3","title":"Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL","status":"UNKNOWN","sponsor":"European Mantle Cell Lymphoma Network","startDate":"2004-07","conditions":"Lymphoma, Mantle-Cell","enrollment":360},{"nctId":"NCT01679860","phase":"PHASE2","title":"Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2006-11","conditions":"Lymphoma, T-Cell, Peripheral","enrollment":92},{"nctId":"NCT00725231","phase":"PHASE3","title":"Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP","status":"UNKNOWN","sponsor":"University of Göttingen","startDate":"2008-02","conditions":"Peripheral T Cell Lymphoma, Unspecified, Angioimmunoblastic Lymphadenopathy, Extranodal NK/T-cell Lymphoma","enrollment":274},{"nctId":"NCT01527422","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL","status":"COMPLETED","sponsor":"Fernando Cabanillas","startDate":"2006-01","conditions":"Lymphoma, Non Hodgkin's Lymphoma","enrollment":60},{"nctId":"NCT01230008","phase":"","title":"Radiotherapy in Primary Mediastinal Lymphoma","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2002-06","conditions":"Adjuvant Radiotherapy on Complete Remission Patients","enrollment":198},{"nctId":"NCT00974324","phase":"PHASE2","title":"Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2009-08","conditions":"T Cell Lymphoma","enrollment":15},{"nctId":"NCT01148446","phase":"PHASE3","title":"R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2003-01","conditions":"Elderly Patients (>65 Years), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"G-CHOP","genericName":"G-CHOP","companyName":"Nanjing Yoko Biomedical Co., Ltd.","companyId":"nanjing-yoko-biomedical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"G-CHOP is a chemotherapy regimen combining gemcitabine, cyclophosphamide, doxorubicin, and vincristine (Oncovin) to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms. Used for Lymphoma (likely non-Hodgkin lymphoma or Hodgkin lymphoma).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}